Department of Geriatrics, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
PLoS One. 2012;7(1):e30185. doi: 10.1371/journal.pone.0030185. Epub 2012 Jan 25.
Calcyclin-binding protein (CacyBP/SIP), identified on the basis of its ability to interact with S100 proteins in a calcium-dependent manner, was previously found to inhibit the proliferation and tumorigenesis of gastric cancer cells in our laboratory. Importantly, the effects of S100 proteins on the biological behavior of CacyBP/SIP in gastric cancer remain unclear. Herein, we report the construction of eukaryotic expression vectors for wild-type CacyBP/SIP and a truncated mutant lacking the S100 protein binding domain (CacyBP/SIPΔS100). The expressions of the wild-type and truncated recombinant proteins were demonstrated by transfection of MKN45 gastric cancer cells. Co-immunoprecipitation assays demonstrated interaction between S100A6 and wild-type CacyBP/SIP in MKN45 cells. Removal of the S100 protein binding domain dramatically reduced the affinity of CacyBP/SIP for S100 proteins as indicated by reduced co-immunoprecipitation of S100A6 by CacyBP/SIPΔS100. The MTT assay, FACS assay, clonogenic assay and tumor xenograft experiment were performed to assess the effect of CacyBP/SIP on cell growth and tumorigenesis in vitro and in vivo. Overexpression of CacyBP/SIP inhibited the proliferation and tumorigenesis of MKN45 gastric cancer cells; the proliferation and tumorigenesis rates were even further reduced by the expression of CacyBP/SIPΔS100. We also showed that S100 proteins negatively regulate CacyBP/SIP-mediated inhibition of gastric cancer cell proliferation, through an effect on β-catenin protein expression and transcriptional activation of Tcf/LEF. Although the underlying mechanism of action requires further investigation, this study provides new insight into the interaction between S100 proteins and CacyBP/SIP, which might enrich our knowledge of S100 proteins and be helpful for our understanding of the development of gastric cancer.
钙周期蛋白结合蛋白(CacyBP/SIP)是基于其与 S100 蛋白在钙离子依赖的方式相互作用的能力而被鉴定的,先前在我们的实验室中发现其能够抑制胃癌细胞的增殖和致瘤性。重要的是,S100 蛋白对 CacyBP/SIP 在胃癌中的生物学行为的影响仍不清楚。在此,我们构建了野生型 CacyBP/SIP 和缺失 S100 蛋白结合域的截断突变体(CacyBP/SIPΔS100)的真核表达载体。通过转染 MKN45 胃癌细胞,证明了野生型和截短重组蛋白的表达。共免疫沉淀实验证明了 S100A6 与 MKN45 细胞中野生型 CacyBP/SIP 的相互作用。S100 蛋白结合域的缺失显著降低了 CacyBP/SIP 与 S100 蛋白的亲和力,这表明 CacyBP/SIPΔS100 与 S100A6 的共免疫沉淀减少。通过 MTT 检测、流式细胞术检测、集落形成实验和肿瘤异种移植实验,评估了 CacyBP/SIP 对体外和体内 MKN45 胃癌细胞生长和致瘤性的影响。CacyBP/SIP 的过表达抑制了 MKN45 胃癌细胞的增殖和致瘤性;表达 CacyBP/SIPΔS100 甚至进一步降低了增殖和致瘤性。我们还表明,S100 蛋白通过对 β-连环蛋白蛋白表达和 Tcf/LEF 的转录激活,负调控 CacyBP/SIP 介导的胃癌细胞增殖抑制。尽管其作用机制尚需进一步研究,但本研究为 S100 蛋白与 CacyBP/SIP 之间的相互作用提供了新的见解,可能丰富我们对 S100 蛋白的认识,并有助于我们理解胃癌的发生发展。